Match!
Eli L. Diamond
Memorial Sloan Kettering Cancer Center
102Publications
19H-index
3,129Citations
Publications 106
Newest
Progress in understanding the rare disease Langerhans cell histiocytosis has stimulated immersive meetings occurring annually over a 30-year period that bring together clinicians, scientists and patients in a unique collaboration.
Source
#1Mayu O. Frank (Rockefeller University)H-Index: 9
#2Takahiko Koyama (IBM)H-Index: 3
Last.Robert B. Darnell (Rockefeller University)H-Index: 75
view all 49 authors...
Prompted by the revolution in high-throughput sequencing and its potential impact for treating cancer patients, we initiated a clinical research study to compare the ability of different sequencing assays and analysis methods to analyze glioblastoma tumors and generate real-time potential treatment options for physicians. A consortium of seven institutions in New York City enrolled 30 patients with glioblastoma and performed tumor whole genome sequencing (WGS) and RNA sequencing (RNA-seq; collec...
1 CitationsSource
Histiocytoses are clonal hematopoietic disorders frequently driven by mutations mapping to the BRAF and MEK1 and MEK2 kinases. Currently, however, the developmental origins of histiocytoses in patients are not well understood, and clinically meaningful therapeutic targets outside of BRAF and MEK are undefined. In this study, we uncovered activating mutations in CSF1R and rearrangements in RET and ALK that conferred dramatic responses to selective inhibition of RET (selpercatinib) and crizotinib,...
Source
The family of juvenile xanthogranuloma family neoplasms (JXG) with ERK-pathway mutations are now classified within the “L” (Langerhans) group, which includes Langerhans cell histiocytosis (LCH) and Erdheim Chester disease (ECD). Although the BRAF V600E mutation constitutes the majority of molecular alterations in ECD and LCH, only three reported JXG neoplasms, all in male pediatric patients with localized central nervous system (CNS) involvement, are known to harbor the BRAF mutation. This retro...
Source
#1Mayu O. Frank (Rockefeller University)H-Index: 9
#2Takahiko Koyama (IBM)H-Index: 3
Last.Robert B. Darnell (Rockefeller University)H-Index: 75
view all 49 authors...
Following publication of the original article [1], it was reported that the given name of the fourteenth author was incorrectly published. The incorrect and the correct names are given below.
Source
Source
Source
#1Jasmine H. FrancisH-Index: 16
#2Eli L. DiamondH-Index: 19
Last.David H. AbramsonH-Index: 57
view all 6 authors...
Background: Central retinal vein occlusion (CRVO) is a visually threatening event that has rarely been observed in patients taking MEK1/2 inhibitors and that may necessitate permanent discontinuation of a potentially efficacious therapy. We investigated the clinical characteristics of CRVO in patients on mitogen-activated protein kinase kinase (MEK) inhibition to better understand their predisposing factors and clinical course. Case Series: This was a single-center, retrospective cohort study (b...
Source
#1Amber C. King (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 3
#2Eli L. Diamond (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 19
Last.Raajit K. Rampal (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 23
view all 7 authors...
Source
#1Philip Jonsson (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 23
#2Andrew Lin (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 5
Last.Barry S. Taylor (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 67
view all 43 authors...
Purpose: The genomic landscape of gliomas has been characterized and now contributes to disease classification, yet the relationship between molecular profile and disease progression and treatment response remain poorly understood. Experimental Design: We integrated prospective clinical sequencing of 1,004 primary and recurrent tumors from 923 glioma patients with clinical and treatment phenotypes. Results: 13% of glioma patients harbored a pathogenic germline variant, including a subset associa...
1 CitationsSource
12345678910